Get the Stockscreener App
10.20
2.51%
0.25
After Hours:
10.20
Amylyx Pharmaceuticals Inc stock is traded at $10.20, with a volume of 1.75M.
It is up +2.51% in the last 24 hours and up +24.69% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
See More
Previous Close:
$9.95
Open:
$10.05
24h Volume:
1.75M
Relative Volume:
1.16
Market Cap:
$909.51M
Revenue:
$-249.00K
Net Income/Loss:
$-187.60M
P/E Ratio:
-4.08
EPS:
-2.5
Net Cash Flow:
$-201.88M
1W Performance:
+8.74%
1M Performance:
+24.69%
6M Performance:
+203.57%
1Y Performance:
+363.64%
1-Day Range:
$9.75
$10.24
1-Week Range:
$9.145
$10.24
52-Week Range:
$2.28
$10.24
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
10.20 | 887.22M | -249.00K | -187.60M | -201.88M | -2.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Guggenheim | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Understanding Amylyx Pharmaceuticals Inc.’s price movement2025 Market Overview & Reliable Volume Spike Alerts - Newser
Sector ETF performance correlation with Amylyx Pharmaceuticals Inc.July 2025 Fed Impact & Accurate Buy Signal Notifications - Newser
Will Amylyx Pharmaceuticals Inc. rebound enough to break evenProfit Target & Consistent Return Investment Signals - Newser
Short interest data insights for Amylyx Pharmaceuticals Inc.2025 Major Catalysts & Fast Exit and Entry Strategy Plans - Newser
Market Catalysts: Will Amylyx Pharmaceuticals Inc. benefit from geopolitical trendsQuarterly Profit Report & Accurate Entry and Exit Point Alerts - خودرو بانک
Will Amylyx Pharmaceuticals Inc. benefit from current market trends2025 Fundamental Recap & Intraday High Probability Setup Alerts - خودرو بانک
Live market analysis of Amylyx Pharmaceuticals Inc.2025 Breakouts & Breakdowns & Community Shared Stock Ideas - Newser
What high frequency data says about Amylyx Pharmaceuticals Inc.Market Sentiment Review & Daily Momentum Trading Reports - Newser
Can Amylyx Pharmaceuticals Inc. stock outperform in a bear marketJuly 2025 Weekly Recap & High Return Trade Guides - خودرو بانک
Is Amylyx Pharmaceuticals Inc. building a consolidation baseWeekly Risk Report & Trade Opportunity Analysis Reports - Newser
Is Amylyx Pharmaceuticals Inc. stock poised for growthWeekly Trend Report & Smart Swing Trading Alerts - Newser
Analyzing Amylyx Pharmaceuticals Inc. with multi timeframe charts2025 Stock Rankings & Safe Entry Trade Reports - Newser
What is Amylyx Pharmaceuticals Inc.’s TAM (Total Addressable Market)July 2025 Patterns & High Conviction Investment Ideas - خودرو بانک
Will Amylyx Pharmaceuticals Inc. outperform during market ralliesJuly 2025 Recap & Verified Momentum Stock Watchlist - خودرو بانک
Is Amylyx Pharmaceuticals Inc. showing insider buyingJuly 2025 Action & AI Optimized Trade Strategies - خودرو بانک
What data driven models say about Amylyx Pharmaceuticals Inc.’s futureWeekly Stock Analysis & Community Consensus Picks - Newser
Is Amylyx Pharmaceuticals Inc. stock a good pick for beginnersGDP Growth & Long-Term Safe Investment Ideas - خودرو بانک
Can technical indicators confirm Amylyx Pharmaceuticals Inc.’s reversalTrend Reversal & Low Risk Entry Point Guides - Newser
What to expect from Amylyx Pharmaceuticals Inc. in the next 30 daysStop Loss & Daily Stock Trend Reports - Newser
What’s next for Amylyx Pharmaceuticals Inc. stock priceAnalyst Upgrade & Momentum Based Trading Signals - Newser
What is the long term forecast for Amylyx Pharmaceuticals Inc. stockExit Point & Smart Investment Allocation Tips - خودرو بانک
Will Amylyx Pharmaceuticals Inc. see short term momentum2025 Volatility Report & Safe Capital Preservation Plans - Newser
Analyzing Amylyx Pharmaceuticals Inc. with risk reward ratio chartsJuly 2025 WrapUp & Daily Volume Surge Signals - Newser
What momentum shifts mean for Amylyx Pharmaceuticals Inc.Market Sentiment Summary & AI Forecast for Swing Trade Picks - Newser
Amylyx Pharmaceuticals Inc. stock trend outlook and recovery pathTrade Risk Report & Weekly Sector Rotation Insights - Newser
Can Amylyx Pharmaceuticals Inc. ride the EV wave2025 Momentum Check & Fast Momentum Entry Tips - خودرو بانک
Amylyx Pharmaceuticals: Strategic Momentum and Pipeline Value in a High-Stakes Biotech Landscape - AInvest
Is this a good reentry point in Amylyx Pharmaceuticals Inc.Earnings Miss & Real-Time Volume Triggers - Newser
Evaluating Amylyx Pharmaceuticals Inc. with trendline analysisQuarterly Profit Summary & Safe Capital Growth Stock Tips - Newser
Dividend Watch: Will Amylyx Pharmaceuticals Inc. benefit from geopolitical trendsJuly 2025 Setups & Technical Pattern Alert System - خودرو بانک
How sentiment analysis helps forecast Amylyx Pharmaceuticals Inc. - Newser
Can Amylyx Pharmaceuticals Inc. keep up with sector leadersQuarterly Earnings Report & Long-Term Safe Return Strategies - خودرو بانک
Can swing trading help recover from Amylyx Pharmaceuticals Inc. lossesWeekly Profit Report & Fast Moving Stock Watchlists - Newser
Price action breakdown for Amylyx Pharmaceuticals Inc.2025 Top Gainers & Verified Momentum Stock Alerts - Newser
Will Amylyx Pharmaceuticals Inc. benefit from rising consumer demandJuly 2025 Setups & Technical Pattern Alert System - خودرو بانک
What is Amylyx Pharmaceuticals Inc. s debt to equity ratioPortfolio Return Report & Reliable Entry Point Alerts - خودرو بانک
Is Amylyx Pharmaceuticals Inc. stock ready for a breakout2025 Earnings Impact & Short-Term High Return Ideas - Newser
Visual trend scoring systems applied to Amylyx Pharmaceuticals Inc.July 2025 Gainers & Capital Protection Trading Alerts - Newser
How Amylyx Pharmaceuticals Inc. stock performs during market volatilityWeekly Risk Report & AI Powered Market Entry Strategies - Newser
Automated trading signals detected on Amylyx Pharmaceuticals Inc.Market Risk Summary & Daily Profit Focused Stock Screening - Newser
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amylyx Pharmaceuticals Inc Stock (AMLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mazzariello Gina | Chief Legal Officer |
Aug 12 '25 |
Sale |
8.07 |
15,000 |
121,102 |
171,969 |
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):